Extracorporeal ultrafiltration for acute exacerbations of chronic heart failure: Report from the acute dialysis quality initiative

International Journal of Artificial Organs

Volumn 28, Issue 5, 2005, Pages 466-476

  Clark, William R ^a,f,g   Paganini, E ^b   Weinstein, D ^b   Bartlett, R ^c   Sheinfeld, G ^d   Ronco, C ^e  

^a Gambro Renal Products   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d MEMORIAL REGIONAL HOSPITAL   (United States)

^e SAN BORTOLO HOSPITAL   (Italy)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g WISHARD MEMORIAL HOSPITAL   (United States)

Author keywords

Heart failure; Hemofiltration; Renal failure; Ultrafiltration

Indexed keywords

CLASSIFICATION (OF INFORMATION); DIALYSIS; ULTRAFILTRATION;

ACUTE EXACERBATIONS; BACKGROUND INFORMATION; CHRONIC HEART FAILURES; CRITICAL ASSESSMENT; FAILURE REPORTS; HEART FAILURE; HEMOFILTRATION; QUALITY INITIATIVES; RENAL FAILURE; WORKGROUPS;

CARDIOLOGY;

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; INOTROPIC AGENT; NESIRITIDE; SPIRONOLACTONE; VASODILATOR AGENT;

ACUTE KIDNEY FAILURE; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE RESISTANCE; DISORDERS OF ACID BASE BALANCE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; HEALTH CARE COST; HEART ARRHYTHMIA; HEART FAILURE; HEART SURGERY; HEART VENTRICLE REMODELING; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; METABOLIC ALKALOSIS; PATHOPHYSIOLOGY; PREVALENCE; QUALITY OF LIFE; SODIUM RESTRICTION; ULTRAFILTRATION; WATER DEPRIVATION;

EID: 20444444676     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880502800507     Document Type: Article

References (55)

1. Kellum JA, Palevsky P, Mehta R, Bellomo R, Ronco C. Acute dialysis quality initiative: Methodology. Curr Opin Crit Care 2002; 8: 500-1.
2. Braunwald E, Colucci WS, Grossman W. Clinical aspects of heart failure. In: Braunwald E, ed. Heart disease: A textbook of cardiovascular medicine. 5th ed. Vol 1. Philadelphia: WB Saunders, 1997: 445-70.
3. American College of Cardiology/American Heart Association Task Force. Guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. Circulation 2001; 104: 2996-3007.
4. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: Findings from the Resource Utilization Among Congestive Heart Failure (REACH) Study. J Am Coll Cardiol 2002; 3: 60-9.
5. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: A manifestation of coronary artery disease. Circulation 1998; 97: 282-9.
6. Francis GS, Benedict C, Johnston DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724-9.
7. Katz AM. The cardiomyopathy of overload: An unnatural growth response in the hypertrophied heart. Ann Intern Med 1994; 121: 363-71.
8. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Study. Circulation 2003; 107: 1486-91.
9. Marin J, Marin E, Gutierrez-Iniguez A, Avendano C, Rodriguez-Martinez MA. Mechanisms involved in the hemodynamic alterations in congestive heart failure as a basis for a rational pharmacological treatment. Pharmacol Ther 2000; 88: 15-31.
10. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind randomized trial. Circulation 2003; 107: 2690-6.
11. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (BNP) concentrations. Lancet 2000; 355: 1126-30.
12. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in the urgent-care setting. J Am Coll Cardiol 2001; 37: 379-85.
13. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000; 343: 246-53.
14. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111: 1487-91.
15. Klein L, O'Connor CM, Gattis WA, et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: Review of trials and practical considerations. Am J Cardiol 2003; 91 (suppl 9A): S18-40.
16. The Criteria Committee of the New York Heart Association. Diseases of the heart and blood vessels: Nomenclature and criteria for diagnosis. 6th ed. Boston: Little Brown, 1964.
17. MacGregor DC, Covell JW, Mahler F, Dilley RB, Ross J. Relations between afterload, stroke volume, and descending limb of Starling's curve. Am J Physiol 1974; 227: 884-90.
18. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001; 96: 132-43.
19. Dei Cas L, Metra M, Leier CV. Electrolyte disturbances in chronic heart failure: Metabolic and clinical aspects. Clin Cardiol 1995; 18: 370-6.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999; 130: 461-70.
22. Clark WR, Mueller BA, Kraus MA, Macias WL. Quantification of creatinine kinetic parameters in patients with acute renal failure. Kidney Int 1998; 54: 554-60.
23. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 1999; 138: 285-90.
24. Hillege HL, Girbes ARJ, de Kam PJ, et al. Renal function, neurohormonal activation, and survivial in patients with chronic heart failure. Circulation 2000; 102: 203-10.
25. Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients ≥ 65 years of age with heart failure. Am J Cardiol 2000; 85: 1110-3.
26. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35: 681-9.
27. Mahon NG, Blackstone EH, Francis GS, Starling RC, Young JB, Lauer MS. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol 2002; 40: 1106-13.
28. Luc G, Bard JM, Juhan-Vague I, et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: The PRIME Study. Arterioscler Thromb Vasc Biol 2003; 23: 1255-61.
29. Silverstein ME, Ford CA, Lysaght MJ, Henderson LW. Treatment of severe fluid overload by ultrafiltration. N Engl J Med 1974; 291: 747-51.
30. Henderson LW, Colton CK, Ford CA, Lysaght MJ. Kinetics of hemodiafiltration. II. Clinical characterization of a new blood cleansing modality. J Lab Clin Med 1975; 85: 372-91.
31. Gerhardt RE, Abdulla AM, Mach SJ, Hudson JB. Isolated ultrafiltration in the treatment of fluid overload in cardiogenic shock. Arch Intern Med 1979; 139: 358-9.
32. Rimondini A, Cipolla C, Bella P, et al. Hemofiltration as a short term treatment for refractory congestive heart failure. Am J Med 1987; 83: 43-8.
33. Simpson IA, Rae AP, Simpson K, et al. Ultrafiltration in the management of refractory congestive heart failure. Br Heart J 1986; 55: 344-7.
34. Dileo M, Pacetti A, Bergerone S, et al. Ultrafiltration in the treatment of refractory congestive heart failure. Clin Cardiol 1988; 11: 449-52.
35. Susini G, Zucchetti M, Bortone F, et al. Isolated ultrafiltration in cardiogenic pulmonary edema. Crit Care Med 1990; 18: 14-7.
36. Marenzi G, Grazi S, Giraldi F, et al. Interrelation of humoral factors, hemodynamics, and fluid and salt metabolism in congestive heart failure: Effect of extracorporeal ultrafiltration. Am J Med 1993; 94: 49-56.
37. Agostoni P, Marenzi G, Pepi M, et al. Isolated ultrafiltration in moderate congestive heart failure, J Am Coll Cardiol 1993; 21: 424-31.
38. Agostoni P, Marenzi G, Lauri G, et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: Failure of furosemide to provide the same result. Am J Med 1994; 96: 191-9.
39. Sakurai T, Homma S, Tabei K, et al. Hemofiltration for the treatment of patients with congestive heart failure. Nippon Rhinsho-Jap J Clin Med 1993; 51: 1310-6.
40. Blake P, Paganini EP. Refractory congestive heart failure: Overview and application of extracorporeal ultrafiltration. Adv Ren Replace Ther 1996; 3: 166-73.
41. Canaud B. Leblanc, M, Leray-Moragues H, Delmas S, Klouche K, Beraud JJ. Slow continuous and daily ultrafiltration for refractory congestive heart failure. Nephrol Dial Transplant 1998; 13 (suppl 4): S51-5.
42. Ronco C, Ricci Z, Bellomo R, Bedogni F. Extracorporeal ultrafiltration for the treatment of overhydration and congestive heart failure. Cardiology 2001; 96: 155-68.
43. Sharma A, Hermann DD, Mehta RL. Clinical benefit and approach of ultrafiltration in acute heart failure. Cardiology 2001; 96: 144-54.
44. Marenzi G, Lauri G, Grazi M, Assanelli E, Campodonico J, Agostoni P. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol 2001; 38: 963-8.
45. Ronco C, Bellomo R, Ricci Z. Hemodynamic response to fluid withdrawal in overhydrated patients treated with intermittent ultrafiltration and slow continuous ultrafiltration: Role of blood volume monitoring. Cardiology 2001; 96: 196-201.
46. Liang KV, Hiniker AR, Williams AW, Karon BL, Greene EL, Redfield MM. Initial clinical experience with a novel ultrafiltration device as a treatment strategy for diuretic resistant, refractory heart failure (Abstract). J Am Coll Cardiol 2005; 45: 169A.
47. Jaski BE, Ha J, Denys BG, Lamba S, Trupp RJ, Abraham WT. Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail 2003; 9: 227-31.
48. Ronco C, Brendolan A, Dan M, Piccinni P, Bellomo R. Machines for continuous renal replacement therapy. Contrib Nephrol 2001; 132: 323-34.
49. Clark WR, Turk JE. The NxStage System One. Semin Dial 2004; 17: 167-70.
50. Huang Z, Henderson LW, Gao D, Clark WR. Hemofiltration and hemodiafiltration for end-stage renal disease. In: Chronic kidney disease: Dialysis and transplantation. Amsterdam, The Netherlands: Elsevier Science B.V. (in press).
51. Clark WR. Quantitative characterization of hemodialyzer solute and water transport. Semin Dial 2001; 14: 32-6.
52. Fonarow GC, Stevenson LW, Steimle AE, et al. Persistently high left ventricular filling pressures predict mortality despite angiotensin converting enzyme inhibition in advanced heart failure (Abstract). Circulation 1994; 90: 1-488.
53. Sutcliffe PD, Aaronson KD, Cody RJ, Koelling TM. Impact of serial changes in cardiac hemodynamics on exercise performance in patients with heart failure due to ischemic and nonischemic cardiomyopathy. Am J Cardiol 2003; 91: 164-8.
54. Stevenson LW, Tillisch JH, Hamilton M, et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction ≤ 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 1990; 66: 1348-54.
55. Shah MR, Stinnett SS, McNulty SE, et al. Hemodynamics as surrogate end points for survival in advanced heart failure: An analysis from FIRST. Am Heart J 2001; 141: 908-14.